Takeda Pharmaceutical Co Ltd
corporate_fare Company Profile
Takeda Pharmaceutical Co Ltd (NYSE:TAK) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for TAK at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-29, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for TAK spans 6-K, 144, 20-F.
Recent high-impact activity:
- Takeda Lifts FY2026 Net Profit Forecast 25.9% to JPY 209B on Strong H1
- Takeda Lifts FY2026 Outlook as H1 Operating Profit Jumps 60%
- Phase 3 Win: Takeda's CLDN18.2 ADC Cuts Death Risk 43% in Advanced Gastric Cancer
- Takeda's First-in-Class Narcolepsy Drug ORZEYFUL Launches in Japan, China
- Zasocitinib Beats Deucravacitinib in Head-to-Head Psoriasis Trial, Boosting Takeda's Blockbuster Hopes
Financial Snapshot
Short Interest & Short Volume
1.09 days to coverFINRA reported short interest of 3,289,262 shares in TAK as of the October 15, 2026 settlement, a 12.7% increase from the prior period — about 1.1 days to cover at its recent average daily volume. On October 30, 2026, 48.5% of TAK volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for TAK, detected from its recent SEC filings · based on capital-structure filings through 2026-06-09.
Share Issuance for LTIP · Significant Value
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
TAK files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.